MARKETS

LiveTV

Gold Rate

Lupin Laboratories Ltd.

BSE: 500258 | NSE: LUPINLAB | Series: NA | ISIN: INE327A01019 | SECTOR: PharmaceuticalsPharmaceuticals

Success

Alert

Please select a Day.

Info

Open trading A/c Open trading A/c

Lupin Laborato Lupin Laboratories Ltd. | BSE 77.75 0.35 (0.45%) | NSE 75.75 0.05 (0.07%) | Trade | Add

BSE Live

Dec 27, 11:22

77.75 0.35 (0.45%)

Volume

No Data Available

362,141

Prev. Close

77.40
Open Price

-

Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)

Lupin Laboratories is not listed on BSE

NSE Live

Dec 27, 11:22

75.75 0.05 (0.07%)

Volume

No Data Available

393,320

Prev. Close

75.70
Open Price

-

Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)

Lupin Laboratories is not listed on NSE

Financials

Print/Copy to Excel : Go

Data Not Available for Cash Flow

Results of Lupin Labs

28.04.2017

Lupin likely to have got VAI status for Goa plant
11.01.2011

Lupin Labs Dec qtr PAT seen up 36.3% at Rs 197.9cr: Karvy

04.11.2020

Lupin Q2 Preview: Adjusted profit may decline sharply on subdued revenue, operating performance
28.05.2020

Lupin Q4 preview: Double-digit decline seen in profit, revenue
18.01.2019

Lupin Q3 PAT may dip 16% YoY to Rs. 286.4 cr: Sharekhan
23.04.2018

Lupin Q4 PAT may dip 5.1% YoY to Rs. 340.7 cr: KR Choksey

01.01.1970

Results of Pharmaceuticals Sector

22.07.2021

Gland Pharma’s new product play for FY22 holds a lot of promise
15.11.2017

Hold Indoco Remedies; target of Rs 250: ICICI Direct
05.10.2017

Buy Natco Pharma; target of Rs 1065: ICICI Direct
18.07.2017

Cipla Q1 PAT may dip 46.52% YoY to Rs 199.6 cr: KR Choksey

28.02.2017

Sanofi India Q4 net declines 58% to Rs 50.5 cr
27.02.2017

Merck Dec-qtr net up 25% at Rs 18 cr
14.02.2017

Claris Lifesciences net profit up 233 pc at Rs 35 cr in Q3
14.02.2017

Sun Pharma Q3 profit dragged by slowdown in US & India sales

18.07.2017

Cipla Q1 PAT may dip 46.52% YoY to Rs 199.6 cr: KR Choksey
13.02.2017

Sun Pharma Q3 profit seen up 27%; US & India biz may grow 10%
09.02.2017

Aurobindo Q3 profit seen up 14%, revenue may grow 10% on US biz
09.02.2017

Lupin Q3 profit seen up 15% to Rs 609cr, US biz may lift revenue

15.02.2017

Ranbaxy deal to kick in, Halol overhang on Sun Pharma:Brokerages
06.02.2017

Good Q3 but Dr Reddy's still far from sustainable growth: Expert
10.11.2016

Sun Pharma Q2 show healthy but margins unsustainable: Nangra
09.11.2016

Low earnings for Lupin to continue for next 2 qtrs: IIFL

Lupin Laboratories Ltd.

Financials

Results of Lupin Labs

Results of Pharmaceuticals Sector

Quick links

News

Corporate Action

Information

Financials

Annual Report

Peer Comparison

Related Searches